Dudediligence.

Barinthus Biotherapeutics plc

BRNSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$15.0MSep ’24$0.00Dec ’24$0.00Sep ’25$0.00Dec ’25
Net income, by quarter
−$8.1MSep ’24−$20.5MDec ’24−$19.6MMar ’25−$21.1MJun ’25−$14.6MSep ’25−$11.1MDec ’25−$5.5MMar ’26−$10.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$268,000$44.7M$802,000$15.0M$0.00
Operating income−$45.2M−$4.0M−$83.9M−$68.0M−$70.6M
Net income−$50.9M$5.3M−$73.3M−$61.1M−$66.4M
Operating cash flow−$32.6M−$14.4M−$50.9M−$28.9M−$48.0M
Free cash flow−$33.7M−$20.6M−$56.3M−$29.8M−$48.0M
Cash$214.1M$194.4M$142.1M$110.7M$70.5M
Debt$159,000none on filenone on filenone on filenone on file
Shares outstanding37.2M37.7M38.6M40.2M40.8M